Skip to main content
Tech.euFundingExplorerBeta

Versantis

Exited

Versantis’ VS-02 is a pre-clinical oral, small molecule drug candidate being developed for the chronic management of HE (hepatic encephalopathy), considered an endemic disease worldwide.

Zurich, Switzerlandwww.versantis.com ↗
Healthtech
← All companies
Total raised
€500k
€500,000
Funding rounds
1
Investors
4
distinct backers
Active since
2025-04
latest 2025-04

Funding by year

EUR raised per year

Funding rounds

1 rounds
DateStageAmountInvestors
2025-04-18Other€500ka French impact fund,Antler,Business Angels,Climate Leaders Fast TrackView deal →

Exit

Type
acquisition
Date
Sep 2022
Value
€41M
Acquiror
GENFIT (France)

Investors

4
a French impact fundAntlerBusiness AngelsClimate Leaders Fast Track

Related news

Similar companies

same sector or country